Effects of the benzimidazole anthelmintic drug flubendazole on rat embryos in vitro

Reproductive Toxicology

Volumn 36, Issue , 2013, Pages 78-87

  Longo, Monica ^a   Zanoncelli, Sara ^a   Colombo, Paolo Angelo ^a   Harhay, Michael Oscar ^b   Scandale, Ivan ^c   Mackenzie, Charles ^d   Geary, Timothy ^e   Madrill, Nicole ^d   Mazué, Guy ^f  

^a Accelera Srl   (Italy)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Drugs for Neglected Diseases initiative (DND)   (Switzerland)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f Aux Fermes de Bosne ^*  (France)

Author keywords

Albendazole; Benzimidazole anthelmintic; Embryotoxicity; Filarial diseases; Flubendazole; Hydrolyzed flubendazole; Reduced flubendazole; Whole embryo culture

Indexed keywords

ALBENDAZOLE; FLUBENDAZOLE;

ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; EMBRYO CULTURE; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; FEMALE; GROWTH RETARDATION; IN VITRO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ANALYSIS; TOXICITY TESTING;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ANIMALS; ANTHELMINTICS; BIOTRANSFORMATION; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; ECTOGENESIS; EMBRYO, MAMMALIAN; FEMALE; HYDROLYSIS; MEBENDAZOLE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; TOXICITY TESTS;

RATTUS;

EID: 84872725778     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.12.004     Document Type: Article

References (34)

1. Taylor M.J., Hoerauf A., Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010, 376:1175-1185.
2. Padgett J.J., Jacobsen K.H. Loiasis African eye worm. Transactions of the Royal Society of Tropical Medicine and Hygiene 2008, 102:983-989.
3. Hotez P.J., Fenwick A., Savioli L., Molyneux D.H. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373:1570-1575.
4. WHO First WHO report on neglected tropical diseases 2010: working to overcome the global impact of neglected tropical diseases 2010, World Health Organization, Geneva.
5. Bockarie M.J., Deb R.M. Elimination of lymphatic filariasis: do we have the drugs to complete the job. Current Opinion in infectious Diseases 2010, 23:617-620.
6. Katiyar D., Singh L.K. Filariasis: current status, treatment and recent advances in drug development. Current Medicinal Chemistry 2011, 18:2174-2185.
7. Hotez P.J. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clinical Pharmacology and Therapeutics 2009, 85:659-664.
8. Hotez P.J., Molyneux D.H., Fenwick A., Kumaresan J., Sachs S.E., Sachs J.D., et al. Control of neglected tropical diseases. New England Journal of Medicine 2007, 357:1018-1027.
9. Harhay M.O., Horton J., Olliaro P.L. Epidemiology and control of human gastrointestinal parasites in children. Expert Review of Anti-infective Therapy 2010, 8:219-234.
10. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Weekly Epidemiological Record 2011, 86:377-388.
11. African Programme for Onchocerciasis Control: meeting of national task forces, September 2011. Weekly Epidemiological Record 2011, 86:541-549.
12. Shenoy R.K., Suma T.K., Kumaraswami V., Rahmah N., Dhananjayan G., Padma S. Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Annals of Tropical Medicine and Parasitology 2009, 103:235-247.
13. Geary T.G., Woo K., McCarthy J.S., Mackenzie C.D., Horton J., Prichard R.K., et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. International Journal for Parasitology 2010, 40:1-13.
14. Geary T.G., Mackenzie C.D. Progress and challenges in the discovery of macrofilaricidal drugs. Expert Review of Anti-infective Therapy 2011, 9:681-695.
15. Mackenzie C.D., Geary T.G. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Review of Anti-infective Therapy 2011, 9(5):497-501.
16. Campbell W.C. Benzimidazoles: veterinary uses. Parasitology Today 1990, 6:130-133.
17. Zahner H., Schares G. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii Acanthocheilonema viteae, Brugia malayi and B. Pahang. Acta Tropica 1993, 52:221-266.
18. Dominguez-Vazquez A., Taylor H.R., Greene B.M., Ruvalcaba-Macias A.M., Rivas-Alcala A.R., Murphy R.P., et al. Flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet 1983, 1(8317):139-143.
19. Lacey E. Mode of action of benzimidazoles. Parasitology Today 1990, 6(4):112-115.
20. European Agency for the evaluation of Medical Products - Veterinary Medicines Evaluation Unit. EMEA/267/97 - Final, October 1997.
21. New D.A.T. Whole embryo culture and the study of mammalian embryos during organogenesis. Biological Reviews 1978, 53:81-122.
22. Brown N.A., Fabro S. Quantitation of rat embryonic development in vitro: a morphological scoring system. Teratology 1981, 24:65-78.
23. Hofbeck C., Eckardt K., Stahlmann R. In vitro embryotoxicity of albendazole and albendazole sulfoxide on rat embryos in culture. Poster presentation at 49th SOT meeting 2010.
24. Eckardt K., Kaltenhauser J., Kilb C., Stahlmann R. Relative potency of albendazole and its metabolite in two in vitro tests for developmental toxicity: the rat whole embryo culture and the mouse embryonic stem cell test. Reproductive Toxicology 2012, 34:378-384.
25. Mantovani A., Ricciardi C., Stazi A.V., Macrì C. Effects observed on gestational day 13 in rat embryos exposed to albendazole. Reproductive Toxicology 1995, 9:265-273.
26. Yoshimura H. Teratogenicity of flubendazole in rats. Toxicology 1987, 43(2):133-138.
27. Yoshimura H. Effect of oral dosing vehicles on the developmental toxicity of flubendazole in rats. Reproductive Toxicology 2003, 17:377-385.
28. Marriner S.E., Morris D.L., Dickson B., Bogan J.A. Pharmacokinetics of albendazole in man. European Journal of Clinical Pharmacology 1986, 30:705-708.
29. World Health Organization (WHO) Report of the WHO informal consultation on hookworm infection and anaemia in girls and women, 5-7 December 1994 1994, WHO, Geneva, Switzerland.
30. Christian P., Khatry S.K., West K.P. Antenatal anthelmintic treatment, birth weight, and infant survival in rural Nepal. Lancet 2004, 364:981-983.
31. Friedman J.F., Mital P., Kanzaria H.K., Olds G.R., Kurtis J.D. Schistosomiasis and pregnancy. Trends in Parasitology 2007, 23:159-164.
32. Gyapong J.O., Chinbuah M.A., Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Tropical Medicine and International Health 2003, 8:1093-1101.
33. Ndyomugyenyi R., Kabatererine N., Olsen A., Pascal Magnussen P. Efficacy of ivermectin and albendazole alone and in combination for treatment of soil-transmitted helminths in pregnancy and adverse events: a randomized open label controlled intervention trial in Masindi District, Western Uganda. American Journal of Tropical Medicine and Hygiene 2008, 79:856-863.
34. Ndibazza J., Muhangi L., Akishule D., Kiggundu M., Ameke C., Oweka J. Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial. Clinical Infectious Diseases 2010, 50:531-540.